Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters.

A standard dose of Adriamycin (60 mg m-2) was administered to 30 patients with inoperable hepatocellular carcinoma, 16 of whom were hyperbilirubinaemic (18-37 mumol l-1). The hyperbilirubinaemic patients experienced marked myelosuppression, but only minor symptomatic side-effects. The degree of neut...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, P. J., Dobbs, N., Kalayci, C., Aldous, M. C., Harper, P., Metivier, E. M., Williams, R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977380/
https://www.ncbi.nlm.nih.gov/pubmed/1316777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977380/
https://www.ncbi.nlm.nih.gov/pubmed/1316777

Ejemplares similares